TCT 2022 | AMULET IDE: Events at 3 Years Using the AMULET Appendage Closure Device

The aim of this study was to assess the 3-year efficacy for the endpoints of the AMULET Occluder (Abbott) left atrial appendage closure device compared with the Watchman 2.5 device.

TCT 2022 | AMULET IDE: Eventos a 3 años con el dispositivo de cierre de orejuela AMULET

The evaluated endpoints were analyzed according to a “per protocol” population, assessing a composite of stroke, systemic embolism, or cardiovascular death. The secondary endpoints were all-cause mortality and cardiovascular death, major bleeding, and a composite of ischemic stroke or systemic embolism.

A total of 917 Amulet Occluder implants and 916 Watchman device implants were observed. The mean age was 75 years old; 58% of patients were male, 55% of whom had paroxysmal atrial fibrillation, with a CHA2DS2-VASC of 4.6.

After a 3-year follow-up, the use of oral anticoagulants was lower with Amulet both at 18 months (3.1% vs. 5.6%; p = 0.01) and at 3 years (3.7% vs. 7.3%; p < 0.01). When analyzing the composite endpoint of stroke, systemic embolism, and cardiovascular death, there was no significant reduction (hazard ratio [HR]: 0.87; 95% confidence interval [CI]: 0.66-1.14; p = 0.31). There was evidence of a non-significant lower trend in all-cause mortality (HR: 0.81; 95% CI: 0.64-1.02; p = 0.07).

Read also: Primary vs Secondary Retrograde Approach in CTO: Differences.

Moreover, the study yielded similar rates for major bleeding events, defined as BARC 3 or more (HR: 1.09, 95% CI: 0.86-1.39; p = 0.46), and thromboembolic events (HR: 1.09; 95% CI: 0.70-1.70; p = 0.69).

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Font: 3-Year Outcomes from the AmplatzerTM AmuletTM Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE). Presentado por Dhanunjaya Lakkireddy en TCT Congress, Boston, EE. UU. 17 septiembre de 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...